CRISPR Therapeutics AG cash flow to debt ratio of -87.36% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

CRISPR Therapeutics AG's free cash flow has decreased 139.11% from $-144.68M last year to $-345.93M, signaling decreasing performance

CRISPR Therapeutics AG's debt to equity ratio is 0.43, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

CRISPR Therapeutics AG's debt has increased relative to shareholder equity from 0.12 last year to 0.43 today, signaling weakened financials

CRISPR Therapeutics AG has negative EBITDA, making leverage ratio unreliable

Interest expense is not separately reported in CRISPR Therapeutics AG's latest filing, so interest coverage cannot be calculated.

CRISPR Therapeutics AG's profit margin has decreased (1.22K%) in the last year from -1.05K% to -13.86K%, signaling decreasing performance

CRISPR Therapeutics AG's short-term assets of $1.99G exceed its short-term liabilities of $149.12M

CRISPR Therapeutics AG's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

CRISPR Therapeutics AG's return on equity of -30.88%, is lower than 15.00%, indicating bad performance

CRISPR Therapeutics AG's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

CRISPR Therapeutics AG had positive net income in only 1.00 out of 5 years, indicating unstable earnings

CRISPR Therapeutics AG has negative free cash flow, indicating the company is burning cash rather than generating it

CRISPR Therapeutics AG has negative free cash flow, indicating cash burn

CRISPR Therapeutics AG's yearly earnings has decreased 58.80% since last year from $-366.25M to $-581.60M, signaling decreasing performance

CRISPR Therapeutics AG's yearly revenue has decreased -89.97% since last year from $35.00M to $3.51M, signaling decreasing performance

ROIC -21.09% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

CRISPR Therapeutics AG's 3-year revenue CAGR of 100.42% is positive, indicating growing revenue over the past 3 years

CRISPR Therapeutics AG had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

CRISPR Therapeutics AG had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

CRISPR Therapeutics AG has insufficient data to evaluate this check.

CRISPR Therapeutics AG has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

CRISPR Therapeutics AG is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

CRISPR Therapeutics AG has negative or missing EBITDA, making EV/EBITDA ratio unreliable

CRISPR Therapeutics AG is overvalued relative to its fair value price of -10.07 based on Earnings Fair Value model

CRISPR Therapeutics AG has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

CRISPR Therapeutics AG has a price-to-book ratio of 2.67x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

CRISPR Therapeutics AG has a price-to-sales ratio of 1.18Kx, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue